Regulatory Filings • Sep 26, 2019
Regulatory Filings
Open in ViewerOpens in native device viewer
Medistims newest generation MiraQTM is approved for sale in Japan
(Oslo, 26th of September 2019) Medistim ASA (OSE: MEDI), a niche market leader within ultrasound technology with headquarter in Norway, that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces that they have received confirmation from its distributor in Japan that its newest product MiraQ is approved for sale in the Japanese market.
MiraQ is Medistim’s newest generation of product for quality assurance within vascular and cardiac surgery. The system is based on ultrasound, and combines blood flow measurement through transit time flow measurement (TTFM) and high frequency ultrasound imaging (HFUS). Medistim’s unique TTFM and HFUS combination provides guidance and control during surgery, in order to avoid or correct issues intraoperatively.
Medistim is now in position to sell MiraQ in all major markets except Canada where an application is in process.
Japan is a substantial market for Medistim with about 400 hospitals performing on average 14 000 cardiac procedures per year. Medistim’s equipment is used in more than 80 % of the procedures. It is expected that a large portion of existing users over time will purchase the new product MiraQ. Medistim’s products are well accepted in the Japanese market and the company is optimistic with regard to future sales of MiraQ in Japan.
About Medistim:
Medistim was established in 1984, and has a track record of profitable growth over the past >15 years. The company is a pioneer within its segment, and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark and Norway, in addition to the about 50 distributors in Europe, Asia, Middle East, Africa, Canada and South America. For more information, visit the Medistim home page: www.Medistim.com
This information is disclosed under Norwegian law (Verdipapirhandelloven §5-12).
For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: [email protected]
CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.